arginine vasopressin has been researched along with snx 482 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dayanithi, G; Lemos, JR; Newcomb, R; Wang, G | 1 |
| Custer, E; Dayanithi, G; Lemos, JR; Ortiz-Miranda, S; Treistman, SN | 1 |
2 other study(ies) available for arginine vasopressin and snx 482
| Article | Year |
|---|---|
An R-type Ca(2+) current in neurohypophysial terminals preferentially regulates oxytocin secretion.
Topics: Animals; Arginine Vasopressin; Calcium Channel Blockers; Calcium Channels, R-Type; Membrane Potentials; Nerve Endings; Nicardipine; omega-Agatoxin IVA; omega-Conotoxins; Oxytocin; Patch-Clamp Techniques; Peptides; Pituitary Gland, Posterior; Rats; Spider Venoms | 1999 |
Micro-opioid receptor preferentially inhibits oxytocin release from neurohypophysial terminals by blocking R-type Ca2+ channels.
Topics: Analgesics, Opioid; Animals; Arginine Vasopressin; Calcium; Calcium Channel Blockers; Calcium Channels, R-Type; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; In Vitro Techniques; Male; Membrane Potentials; Nerve Endings; Neuropeptides; Oxytocin; Pituitary Gland, Posterior; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Spider Venoms | 2005 |